Evidence map›Paper›PMID 29944670›Full record

ArticlePloS one2018

Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.

Anne Hwang, Christopher Shi, Edward Zhu, Farha Naaz, Ping Zhou, Zainab Rasheed, Michelle Liu, Lindsey S Jung, Bin Duan, Jingsong Li and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. From NASH to HCC: current concepts and future challenges.Nature reviews. Gastroenterology & hepatology · 2019
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Anne HwangDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Christopher ShiDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Edward ZhuDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Farha NaazDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Ping ZhouDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Zainab RasheedDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Michelle LiuDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Lindsey S JungDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Bin DuanDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Jingsong LiDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Kai JiangDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Latha PakaDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Satishkumar V GadhiyaDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Dibyendu DanaDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Quaisar AliDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Michael A YaminDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Itzhak D GoldbergDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Prakash NarayanDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.ORCID 0000-0002-7007-0245
Angion (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although cirrhosis is a key risk factor for the development of hepatocellular carcinoma (HCC), mounting evidence indicates that in a subset of patients presenting with non-alcoholic steatohepatitis (NASH) HCC manifests in the absence of cirrhosis. Given the sheer size of the ongoing non-alcoholic fatty liver disease (NAFLD) epidemic and the dismal prognosis associated with late-stage primary liver cancer there is an urgent need for HCC surveillance in the NASH population. Using serum levels of HCC biomarkers as vectors and biopsy-proven HCC or no HCC as outputs / binary classifier, a supervised learning campaign was undertaken to develop a minimally invasive technique for making a diagnosis of HCC in a clinically relevant model of NASH. Adult mice randomized to control diet or a fast food diet (FFD) were followed for up to 14 mo and serum level of a panel of HCC-relevant biomarkers was compared with liver biopsies at 3 and 14 mo. Both NAFLD Activity Score (NAS) and hepatic hydroxyproline content were elevated at 3 and 14 mo on FFD. Picrosirius red staining of liver sections revealed a filigree pattern of fibrillar collagen deposition with no cirrhosis at 14 mo on FFD. Nevertheless, 46% of animals bore one or more tumors on their livers confirmed as HCC in hematoxylin-eosin-stained liver sections. In this training set, receiver operating characteristic (ROC) curves analysis for serum levels of the HCC biomarkers osteopontin (OPN), alpha-fetoprotein (AFP) and Dickkopf-1 (DKK1) returned concordance-statistic/area under ROC curve of ≥ 0.89. Serum levels of OPN (threshold, 218 ng/mL; sensitivity, 82%; specificity, 86%), AFP (136 ng/mL; 91%; 97%) and DKK1 (2.4 ng/mL; 82%; 81%) diagnostic for HCC were confirmed in a test set comprising mice on control diet or FFD and mice subjected to hepatic ischemia-reperfusion injury. These data suggest that levels of circulating OPN, AFP and DKK1 can be used to make a diagnosis of HCC in a clinically relevant model of NASH.

Indexed as

AnimalsBiomarkers, TumorCarcinoma, HepatocellularDisease Models, AnimalHumansLiverLiver NeoplasmsMaleMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseSupervised Machine LearningBiomarkers, Tumor

Identifiers

PMID29944670
PMCPMC6019748
OpenAlexW2811469472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.